Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

SOPHIA ANTIPOLIS, France, October 22 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today reported financial results for the nine months ended September 30, 2008.

Key highlights of the third quarter of 2008:

- Positive top-line results from the 302 study for naproxcinod. The study

met all three co-primary efficacy endpoints at week-13 (p<0.001) and

naproxcinod 750 mg bid comfortably met the main secondary endpoint of

non-inferiority to naproxen 500 mg bid at week-13 and 26. Blood

pressure data from the 302 study also supported naproxcinod's non-

detrimental effect on blood pressure.

- Good overall long term safety demonstrated for both doses of

naproxcinod in the 301 extension study, with no unexpected safety

findings. In addition, the patients' mean blood pressure remained

stable for the 52 weeks following the completion of the 301 study,

suggesting that naproxcinod does not increase blood pressure over time.

- Exclusive agreement signed with Capsugel, the leading

producer of two-piece capsules, for the commercial manufacture of

naproxcinod capsules. Capsugel will be responsible for the formulation

and encapsulation of naproxcinod API.

- Enrollment of 417 osteoarthritis patients with controlled

hypertension successfully completed in two Ambulatory Blood Pressure

Monitoring (ABPM) trials, the 111 and 112 studies. These trials are

designed to assess the 24-hour blood pressure profile of naproxcinod,

in comparison to ibuprofen and naproxen.

- PF-03187207 demonstrated an improvement over Xalatan(R) 0.005% in a

Japanese phase 2 study in glaucoma, although the primary endpoint

at day 28 was not met. NicOx is currently discussing the rights to

PF-03187207 with Pfizer to allow its potential continued development

and commercialization, following Pfi
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
(Date:5/23/2013)... 23, 2013 The New Jersey chapter ... Black Data Processing Associates (BDPA), is hosting its 10th ... 2013. This all-day event will encourage students and their ... ins and outs from many of the industries’ finest ... the New Jersey Institute of Technology, the event will ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2
... writing this article, we are 42 days away from the Olympics ... thinking, "But wait, isn't this meeting normally in June?", you would ... in June, but not this year. , ,The BIO ... about 2 months earlier than normal for a couple of key ...
... revenue led Third Wave Technologies to a loss of ... the loss was expected share price rose slightly in light trading. ... a rough patch. It has a new focus on the ... ,Third Wave's 2005 revenue was $23.9 million, compared to 2004 revenue ...
... Information technology suffers from one bugbear above all: complexity. That ... night and explored by panelists and attendees of the ... that will win," said Frank Timons, an analysit with R.W. ... by "too many applications, too many vendors, too many business ...
Cached Biology Technology:42 days until the 2006 Olympics of Biotechnology in Chicago 242 days until the 2006 Olympics of Biotechnology in Chicago 342 days until the 2006 Olympics of Biotechnology in Chicago 442 days until the 2006 Olympics of Biotechnology in Chicago 5Simplicity appeals to CIOs, but it's no easy task 2Simplicity appeals to CIOs, but it's no easy task 3
(Date:5/23/2013)... In an age when microbial pathogens are growing increasingly ... infection, a team of Wisconsin scientists has synthesized a ... bacteria that cause staph infections. , Writing online in ... a group led by University of Wisconsin-Madison chemistry Professor ... "quorum sensing" behavior of Staphylococcus aureus , a ...
(Date:5/22/2013)... National Lung Screening Trial (NLST) investigators also conclude ... mortality with low-dose computed tomography (LDCT) versus chest ... primary paper is achievable at experienced screening centers ... more information to share with their patients about ... screening following today,s publication in the New ...
(Date:5/22/2013)... have developed a novel technique that can detect molecular ... that is one of the most important, though time-consuming, ... a paper in Nature , post-doctoral researcher David ... Schnell of the Center for Free-Electron Laser Science (CFEL) ... finely-tuned microwave fields to identify molecular variants apart, and ...
Breaking Biology News(10 mins):University of Wisconsin chemists find new compounds to curb staph infection 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Detecting mirror molecules 2Detecting mirror molecules 3
... A study by UC Irvine ecologists finds that ... an average of 20 percent, countering the belief that ... Faster plant growth means the tropics will take in ... effects are unclear. Over the next century, nitrogen pollution ...
... As reported in this week,s issue of "New Scientist" magazine, ... indicates that what is on one,s mind about politics may ... who has researched this topic for a number of years, ... than 12,000 twins in the United States and supplemented it ...
... birds originate around the time of the dinosaurs, demise, ... The question is at the center of a sometimes ... are based on the fossil record, and scientists who ... A new analysis by researchers at the University of ...
Cached Biology News:Nitrogen pollution boosts plant growth in tropics by 20 percent 2Avian origins: new analysis confirms ancient beginnings 2
... extended-length microarrays are custom designed to meet ... are available: 8,455 features per array (2 ... features per array (1 array/slide). ... length - This extended length delivers ...
... OPEP-01009 is a 16 amino acid (amino acids 3-18) synthetic ... The sequence of this peptide is (amino to carboxy ... - V - K - L - R - A ... - K(18). This peptide may be used for ...
... Microarrays designed for pathway studies, ... protein (PTB) Studies built on the ... synthesis platform. These microarrays are available ... Peptide Microarray Service. Custom ...
... Tissue Arrays are intended for laboratory research ... fixed in neutral buffered formalin and embedded ... was performed by certified pathologists. Tissue ... and relocated into a new recipient paraffin ...
Biology Products: